Moreover, pathological analysis of tumor and healthy brain tissues unveiled well-defined tumor boundaries, highlighting the capacity of the MPA-Pip-abt-510 probe to precisely visualize the CD36 protein at the molecular level. Given its rapid tumor-targeting abilities, durable retention, and accurate outlining of tumor boundaries, MPA-Pip-abt-510 emerges as a promising CD36-targeted fluorescence contrast agent and expands the toolbox of glioma fluorescent probes for surgical navigation.

These findings are in line with the results of recent trials testing new agents on comparable patient cohorts and provide initial evidence of clinical benefit for patients with refractory/relapsed MM treated with MP0250 in combination with bortezomib/dexamethasone. Further clinical evaluation in the emerging MM treatment landscape would be required to confirm the clinical potential of MP0250.

High MPA-ABT-510 accumulation was evident in A549 intestinal metastases models, as evidenced by tumor-to-colorectal fluorescence ratios of 4.27 ± 0.11. MPA-ABT-510 exhibits superior imaging capabilities with minimal safety concerns, so it is a promising candidate for NSCLC surgical navigation.

P3, N=410, Recruiting, AVEO Pharmaceuticals, Inc.

P3, N=410, Recruiting, AVEO Pharmaceuticals, Inc. | Not yet recruiting --> Recruiting

P3, N=410, Not yet recruiting, AVEO Pharmaceuticals, Inc.

Conclusions The YYB101 and irinotecan combination showed modest efficacy and tolerable adverse events in refractory metastatic/recurrent CRC. Ongoing biomarker analyses aim to identify genomic and transcriptomic variables associated with long-term disease control.

P2, N=78, Completed, University of Arizona | N=60 --> 78

Furthermore, MPA-PEG-r-ABT-510 exhibited an antiangiogenic effect via tube information assay with human umbilical vein endothelial cells. Overall, MPA-PEG-r-ABT-510 presents rapid and precise tumor delineation characteristics, thereby making it a desirable tool for CRC imaging and surgical navigation.

In this phase Ib trial, ficlatuzumab, gemcitabine, and albumin-bound paclitaxel were associated with durable treatment responses and increased rates of hypoalbuminemia and edema.

The ficlatuzumab-cetuximab arm met significance criteria for PFS and warrants phase III development. HPV-negative HNSCC merits consideration as a selection criterion.